BGI Genomics Co Ltd (300676) - Net Assets
Based on the latest financial reports, BGI Genomics Co Ltd (300676) has net assets worth CN¥8.54 Billion CNY (≈ $1.25 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥11.35 Billion ≈ $1.66 Billion USD) and total liabilities (CN¥2.81 Billion ≈ $410.62 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300676 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.54 Billion |
| % of Total Assets | 75.27% |
| Annual Growth Rate | 36.53% |
| 5-Year Change | -8.83% |
| 10-Year Change | 149.31% |
| Growth Volatility | 84.56 |
BGI Genomics Co Ltd - Net Assets Trend (2012–2025)
This chart illustrates how BGI Genomics Co Ltd's net assets have evolved over time, based on quarterly financial data. See BGI Genomics Co Ltd (300676) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for BGI Genomics Co Ltd (2012–2025)
The table below shows the annual net assets of BGI Genomics Co Ltd from 2012 to 2025. For live valuation and market cap data, see BGI Genomics Co Ltd (300676) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥8.61 Billion ≈ $1.26 Billion |
-7.16% |
| 2024-12-31 | CN¥9.27 Billion ≈ $1.36 Billion |
-7.32% |
| 2023-12-31 | CN¥10.00 Billion ≈ $1.46 Billion |
-2.13% |
| 2022-12-31 | CN¥10.22 Billion ≈ $1.50 Billion |
+8.26% |
| 2021-12-31 | CN¥9.44 Billion ≈ $1.38 Billion |
+56.68% |
| 2020-12-31 | CN¥6.03 Billion ≈ $881.76 Million |
+35.17% |
| 2019-12-31 | CN¥4.46 Billion ≈ $652.35 Million |
+7.89% |
| 2018-12-31 | CN¥4.13 Billion ≈ $604.67 Million |
-2.95% |
| 2017-12-31 | CN¥4.26 Billion ≈ $623.07 Million |
+23.33% |
| 2016-12-31 | CN¥3.45 Billion ≈ $505.22 Million |
+8.93% |
| 2015-12-31 | CN¥3.17 Billion ≈ $463.80 Million |
+116.27% |
| 2014-12-31 | CN¥1.47 Billion ≈ $214.45 Million |
+145.09% |
| 2013-12-31 | CN¥597.94 Million ≈ $87.50 Million |
+297.65% |
| 2012-12-31 | CN¥150.37 Million ≈ $22.00 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BGI Genomics Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5330.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.06 Billion | 36.00% |
| Other Components | CN¥5.44 Billion | 64.00% |
| Total Equity | CN¥8.49 Billion | 100.00% |
BGI Genomics Co Ltd Competitors by Market Cap
The table below lists competitors of BGI Genomics Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ACME Solar Holdings Limited
NSE:ACMESOLAR
|
$2.18 Billion |
|
Grupo Aval
NYSE:AVAL
|
$2.18 Billion |
|
Tokai Carbon Korea Co. Ltd
KQ:064760
|
$2.18 Billion |
|
Remy Cointreau
PA:RCO
|
$2.18 Billion |
|
Netcompany Group A/S
CO:NETC
|
$2.17 Billion |
|
Pertamina Geothermal Energy
JK:PGEO
|
$2.17 Billion |
|
Royce Value Closed Fund
NYSE:RVT
|
$2.17 Billion |
|
Nextnav Acquisition Corp
NASDAQ:NN
|
$2.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BGI Genomics Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,134,857,139 to 8,494,244,178, a change of -640,612,961 (-7.0%).
- Net loss of 616,655,148 reduced equity.
- Dividend payments of 17,284,158 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-616.66 Million | -7.26% |
| Dividends Paid | CN¥17.28 Million | -0.2% |
| Other Changes | CN¥-6.67 Million | -0.08% |
| Total Change | CN¥- | -7.01% |
Book Value vs Market Value Analysis
This analysis compares BGI Genomics Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 19.42x to 1.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥1.83 | CN¥35.52 | x |
| 2013-12-31 | CN¥4.89 | CN¥35.52 | x |
| 2014-12-31 | CN¥4.64 | CN¥35.52 | x |
| 2015-12-31 | CN¥9.09 | CN¥35.52 | x |
| 2016-12-31 | CN¥9.29 | CN¥35.52 | x |
| 2017-12-31 | CN¥10.94 | CN¥35.52 | x |
| 2018-12-31 | CN¥10.13 | CN¥35.52 | x |
| 2019-12-31 | CN¥10.91 | CN¥35.52 | x |
| 2020-12-31 | CN¥14.80 | CN¥35.52 | x |
| 2021-12-31 | CN¥22.64 | CN¥35.52 | x |
| 2022-12-31 | CN¥24.58 | CN¥35.52 | x |
| 2023-12-31 | CN¥23.91 | CN¥35.52 | x |
| 2024-12-31 | CN¥22.15 | CN¥35.52 | x |
| 2025-12-31 | CN¥20.31 | CN¥35.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BGI Genomics Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16.64%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.38x
- Recent ROE (-7.26%) is below the historical average (13.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 72.18% | 10.28% | 0.79x | 8.86x | CN¥70.41 Million |
| 2013 | 33.98% | 12.97% | 0.70x | 3.74x | CN¥95.89 Million |
| 2014 | 2.37% | 2.48% | 0.55x | 1.73x | CN¥-90.47 Million |
| 2015 | 8.47% | 19.88% | 0.34x | 1.26x | CN¥-47.40 Million |
| 2016 | 9.90% | 19.44% | 0.40x | 1.26x | CN¥-3.29 Million |
| 2017 | 9.60% | 19.00% | 0.41x | 1.23x | CN¥-16.77 Million |
| 2018 | 9.54% | 15.24% | 0.49x | 1.27x | CN¥-18.47 Million |
| 2019 | 6.33% | 9.87% | 0.47x | 1.37x | CN¥-160.36 Million |
| 2020 | 35.37% | 24.89% | 0.74x | 1.92x | CN¥1.50 Billion |
| 2021 | 15.68% | 21.60% | 0.47x | 1.53x | CN¥529.70 Million |
| 2022 | 7.97% | 11.38% | 0.49x | 1.43x | CN¥-204.85 Million |
| 2023 | 0.94% | 2.14% | 0.32x | 1.38x | CN¥-893.02 Million |
| 2024 | -9.88% | -23.34% | 0.31x | 1.37x | CN¥-1.82 Billion |
| 2025 | -7.26% | -16.64% | 0.32x | 1.38x | CN¥-1.47 Billion |
Industry Comparison
This section compares BGI Genomics Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,736,808,821
- Average return on equity (ROE) among peers: 19.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BGI Genomics Co Ltd (300676) | CN¥8.54 Billion | 72.18% | 0.33x | $2.17 Billion |
| Berry Genomics Co Ltd (000710) | $41.15 Million | 36.01% | 2.32x | $406.61 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $110.32 Million | 15.56% | 0.62x | $1.67 Billion |
| Hangzhou Tigermed Consulting (300347) | $146.03 Million | 32.73% | 0.28x | $4.33 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $385.67 Million | 35.53% | 0.12x | $972.92 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $2.93 Billion | 8.79% | 0.26x | $470.71 Million |
| Maccura Biotechnology Co Ltd (300463) | $6.53 Billion | 10.85% | 0.25x | $742.36 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $2.53 Billion | 14.31% | 0.13x | $505.18 Million |
| Amoy Diagnostics Co Ltd (300685) | $1.70 Billion | 15.35% | 0.14x | $959.68 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.25 Billion | 8.85% | 0.18x | $507.55 Million |
About BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exom… Read more